More Data Support Olaparib-Abiraterone in BRCA-Mutant Prostate Cancer
Combining olaparib (Lynparza) with abiraterone acetate (Zytiga) as first-line therapy for biomarker-selected patients with metastatic castration-resistant prostate cancer significantly improved progression-free survival (PFS) versus either agent alone, according to findings from a small phase II trial presented at this year’s Genitourinary Cancers Symposium. In this exclusive MedPage Today video, Daniel Geynisman, MD, of Fox Chase […]
FDA OKs Olaparib-Abiraterone for Metastatic Prostate Cancer
The FDA has approved the PARP inhibitor olaparib (Lynparza) in combination with abiraterone (Zytiga) for BRCA-mutated metastatic castration-resistant prostate cancer (mCRPC), the agency announced Wednesday. Adult patients should be selected for the combination therapy — which is given with prednisone (or prednisolone) — based on an FDA-approved companion diagnostic test to detect deleterious or suspected […]
FDA Staff Not Sold on Broad Olaparib Indication in Metastatic CRPC
Olaparib (Lynparza) plus abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (CRPC) is only clearly effective in patients with BRCA mutations, FDA staff contended in a briefing document released ahead of an advisory committee meeting. On Friday, the FDA is asking its Oncologic Drugs Advisory Committee (ODAC) to weigh in on whether a […]
Add-On Olaparib Continues to Show Benefit in First-Line Treatment of mCRPC
SAN FRANCISCO — Adding the PARP inhibitor olaparib (Lynparza) to standard-of-care abiraterone (Zytiga) as initial treatment for metastatic castration-resistant prostate cancer (mCRPC) extended median progression-free survival (PFS), according to final results of the double-blind phase III PROpel study reported here. There was also a trend toward an improvement in median overall survival (OS). At the […]
Two PARP Inhibitors Impress as First-Line Add-Ons in mCRPC
Adding PARP inhibition to first-line abiraterone (Zytiga) reduced the risk of radiographic progression or death in metastatic castration-resistant prostate cancer (mCRPC), a pair of phase III studies showed. In PROpel, patients who received olaparib (Lynparza) along with abiraterone plus prednisone had a roughly 8-month improvement in median radiographic progression-free survival (rPFS) versus those assigned placebo […]